An observational study in Multiple Sclerosis, sponsored by Wayne State University. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-11-25.
Sponsored by Wayne State University · Observational
The primary goal of this study will be to explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies using conventional and non-conventional MRI sequences.
3,524 studies on the registry are indexed under Multiple Sclerosis; 668 are open to participants now.
Browse Multiple Sclerosis studies →Wayne State University is the lead sponsor of 229 studies on the registry; 34 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with RRMS who are participating in the CARE MS I and CARE MS II studies and are receiving either alemtuzumab or interferon beta-1a SC
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies
Compare the effect of alemtuzumab to interferon beta-1a SC on non-conventional MRI outcomes
No study locations are listed for this record.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.